The COBRRA Trial and the Questions that Remain

Clinicians have long relied on indirect comparisons when choosing between direct oral anticoagulants (DOACs) for VTE. The COBRRA trial changed that.

Join experts Behnood Bikdeli, Lana Castellucci, and David Jiménez as they discuss:

• The landmark COBRRA trial and its implications for VTE treatment

• How bleeding risk, adherence, and patient preferences influence DOAC selection

• When alternatives to apixaban may still be preferred

• The challenges of conducting head-to-head anticoagulation trials

• Global barriers to DOAC access and the next unanswered questions in the field

Tune in now and subscribe to Clot, Clot, Who's There? for more expert conversations bridging science, practice, and global perspectives in thrombosis, hemostasis, and vascular medicine.